Intended for healthcare professionals


Scotland approves MS drug that was rejected in England and Wales

BMJ 2021; 372 doi: (Published 09 February 2021) Cite this as: BMJ 2021;372:n391
  1. Bryan Christie
  1. Edinburgh, UK

A drug that can reduce the number of relapses suffered by people with multiple sclerosis (MS) has been approved for use in Scotland despite a provisional decision to reject it in England and Wales.

Ozanimod (Zeposia) is a daily tablet that has been shown in a two year clinical trial to reduce relapses by around 38% compared with an existing treatment, injectable β …

View Full Text

Log in

Log in through your institution


* For online subscription